Previous studies have established that the employment of EGFR tyrosine-kinase inhibitors (EGFR-TKIs) (such as erlotinib) have achieved encouraging progress in treating patients with pancreatic cancer, unfortunately, after the initial response, many patients would inevitably acquire resistance to erlotinib (9). This evidence concerns the gene EGFR and pancreatic neoplasm.